Bassem Chehab
YOU?
Author Swipe
View article: Combining Optical Coherence Tomography and Fractional Flow Reserve for Decision Making in Percutaneous Coronary Intervention: Insights From the FUSION Study
Combining Optical Coherence Tomography and Fractional Flow Reserve for Decision Making in Percutaneous Coronary Intervention: Insights From the FUSION Study Open
Fractional flow reserve and OCT provide distinct yet complementary information that significantly impacts decision making during PCI. Specifically, FFR informs revascularization decision making, while OCT plays a crucial role in device siz…
View article: Multicenter Prospective Assessment of Coronary Microvascular Dysfunction
Multicenter Prospective Assessment of Coronary Microvascular Dysfunction Open
In a prospective assessment of invasive testing for CMD/VSA, we observed varied procedural and technical approaches. Testing was rapid, and a final diagnosis of CMD or VSA was common with immediate implications for patient management. Furt…
View article: Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial Open
Background and Aims The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy v…
View article: Echocardiographic Imaging Considerations for Post-Implant Evaluation of the Transcatheter EVOQUE Tricuspid Valve Replacement System
Echocardiographic Imaging Considerations for Post-Implant Evaluation of the Transcatheter EVOQUE Tricuspid Valve Replacement System Open
The transcatheter EVOQUE tricuspid valve replacement system is an approved device for the treatment of patients with symptomatic severe tricuspid regurgitation despite medical therapy both in the United States and in Europe. Specific imagi…
View article: Safety and Efficacy of Cobalt Chromium Everolimus‐Eluting Stents for Treatment of In‐Stent Restenosis: An ILUMIEN IV Substudy
Safety and Efficacy of Cobalt Chromium Everolimus‐Eluting Stents for Treatment of In‐Stent Restenosis: An ILUMIEN IV Substudy Open
Background The optimal management strategy for in‐stent restenosis (ISR) remains unclear. We aimed to determine the safety and efficacy of percutaneous coronary intervention with XIENCE cobalt chromium everolimus‐eluting stents (EES) for t…
View article: Predictors and Trends of New Permanent Pacemaker Implantation: A Subanalysis of the International Navitor IDE Study
Predictors and Trends of New Permanent Pacemaker Implantation: A Subanalysis of the International Navitor IDE Study Open
The 30-day rate of new PPI in the Navitor IDE study is associated with patient pre-existing baseline conduction disturbances and implantation depth.
View article: 1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program
1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program Open
This analysis aimed to evaluate the effect of 1- versus 3-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in older patients. Data from 3 prospective, single-arm studies (XIENCE Short DAPT Program), inc…
View article: 1-Year Outcomes With Fourth-Generation Mitral Valve Transcatheter Edge-to-Edge Repair From the EXPAND G4 Study
1-Year Outcomes With Fourth-Generation Mitral Valve Transcatheter Edge-to-Edge Repair From the EXPAND G4 Study Open
M-TEER with the fourth-generation M-TEER device was safe and effective at 1 year, with durable reductions in MR severity to ≤1+ in more than 90% of patients and concomitant improvements in functional status and quality of life.
View article: 1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI
1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI Open
Between 1 and 12 months after PCI, 1-month compared with 3-month DAPT was associated with similar rates of all-cause death or MI and a reduced rate of BARC types 2 to 5 bleeding, irrespective of OAC treatment.
View article: ISR vs De Novo Lesion Treatment During OCT-Guided PCI: Insights From the LightLab Initiative
ISR vs De Novo Lesion Treatment During OCT-Guided PCI: Insights From the LightLab Initiative Open
In this real-world cohort of patients who underwent OCT-guided PCI, ISR procedures were longer and final minimum stent area and percent expansion were lower despite greater use of advanced lesion modification. OCT frequently altered physic…
View article: Real-World Outcomes of Fourth-Generation Mitral Transcatheter Repair
Real-World Outcomes of Fourth-Generation Mitral Transcatheter Repair Open
This study demonstrates for the first time the effectiveness and safety of MitraClip G4 System at 30 days in a cohort of >1,000 patients with MR in a contemporary, real-world setting.
View article: Expanding the Spectrum of TEER Suitability
Expanding the Spectrum of TEER Suitability Open
Patients previously deemed TEER unsuitable can be safely and effectively treated with the mitral TEER fourth-generation device.
View article: Early outcomes of transcatheter mitral valve replacement with the Tendyne system in severe mitral annular calcification
Early outcomes of transcatheter mitral valve replacement with the Tendyne system in severe mitral annular calcification Open
In patients with MR and severe MAC, TMVR with the Tendyne valve was associated with encouraging acute outcomes, midterm durability, and clinical improvement. Dedicated TMVR therapy may have a future role in these anatomically challenging, …
View article: Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI Open
Among HBR patients undergoing PCI, 1 month of DAPT, compared with 3 months of DAPT, was associated with similar ischemic outcomes and lower bleeding risk. (XIENCE 90 Study; NCT03218787; XIENCE 28 USA Study; NCT03815175; XIENCE 28 Global St…
View article: 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation Open
Among HBR patients undergoing PCI with cobalt-chromium everolimus-eluting stents, DAPT for 1 or 3 months was noninferior to 6 or 12 months of DAPT for ischemic outcomes and may be associated with less major bleeding and a low incidence of …
View article: Real-World Experience With the SAPIEN 3 Ultra Transcatheter Heart Valve: A Propensity-Matched Analysis From the United States
Real-World Experience With the SAPIEN 3 Ultra Transcatheter Heart Valve: A Propensity-Matched Analysis From the United States Open
Background: Paravalvular regurgitation (PVR) after transcatheter aortic valve replacement is associated with adverse clinical outcomes. The SAPIEN 3 Ultra (Ultra) is a new generation balloon-expandable transcatheter heart valve with a modi…
View article: Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System
Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System Open
Dataset from Fontana GP, Bedogni F, Groh M, Smith D, Chehab BM, Garrett HE Jr, Yong G, Worthley S, Manoharan G, Walton A, Hermiller J, Dhar G, Waksman R, Ramana RK, Mahoney P, Asch FM, Chakravarty T, Jilaihawi H, Makkar RR. Safety Profile …
View article: Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System
Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System Open
Dataset from Fontana GP, Bedogni F, Groh M, Smith D, Chehab BM, Garrett HE Jr, Yong G, Worthley S, Manoharan G, Walton A, Hermiller J, Dhar G, Waksman R, Ramana RK, Mahoney P, Asch FM, Chakravarty T, Jilaihawi H, Makkar RR. Safety Profile …